Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes

British Journal of Haematology

Volumn 105, Issue 1, 1999, Pages 141-148

  Stasi, Roberto ^a   Pagano, Adalberto ^a   Terzoli, Eomondo ^b   Amadori, Sergio ^c  

^a REGINA APOSTOLORUM HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Erythropoietin; GM CSF; Myelodysplastic syndrome; Treatment

Indexed keywords

MILOGEN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CASE REPORT; CYTOPENIA; DOSE RESPONSE; DRUG EFFECT; ERYTHROCYTE COUNT; ERYTHROPOIESIS; FEMALE; HUMAN; IMMUNOTHERAPY; LEUKOCYTE COUNT; LEUKOPOIESIS; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; AGED, 80 AND OVER; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PLATELET COUNT;

EID: 0032918396     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.1999.01313.x     Document Type: Article

References (31)

1. Antin, J.H., Smith, B.R.. Holmes, W. & Rosenthal, D.S. (1988) Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood, 72, 705-713.
2. Aoki, A. & Shibata, A. (1992) In vitro studies of erythropoiesis in patients with aplastic anemia and myelodysplastic syndromes: a possible tool for the prospective determination of the clinical effectiveness of growth factors. Hématologie Pathology. 6, 143-153.
3. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology. 51, 189-199.
4. Bernell, P., Stenke, L., VVallvik. J.. Hippe, E. & Hast, R. (1996) A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anemia in myelodysplastic syndromes. Leukemia Research, 20, 693-699.
5. Broxmeyer, H.. Cooper, S. & Vadhan-Raj, S. (1989) Cell cycle status of erythroid (BFU-E) progenitor cells from the bone marrow of patients on a clinical trial with purified recombinant granulocytemacrophage colony-stimulating factor. Experimental llematology, 17,455-459.
6. Donahue. R.E., Emerson, S.G., Wang, E,A VVong, G.G., Clark, S.C. & Nathan, D.G. (1985) Demonstration of burst-promoting activity of recombinant human GM-CSF on circulating erythroid progenitors using an assay involving the delayed addition of erythropoietin. Blood. 66, 1479-1481.
7. Erslev, A. (1991) Erythropoietin. New England Journal of Medicine, 324, 1339-1344.
8. Faquin. W.C., Scheider, T.J. & Goldberg. M.A. (1992) Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 79, 1987-1994.
9. Ganser, A., Seipelt, G., Lindemann, A., Ottmann, O.G.. Falk, S., Eder, M.. Herrmann, F., Becher, R., Hoffken. K. & Buchner, T. (1990) Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood. 76, 455-462.
10. Ganser, A., Volkers. B.. Greher. ]., Ottmann, O.G., Walthcr. F., Becher. R.. Bergmann, L, Schulz, G. & Hoelzer, D. (1989) Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes: a phase I/II trial. Blood. 73, 31-37.
11. Greenbcrg, P.L., Cox, C., LeBeau, M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin. T.. Oscier, D., Ohyashiki, K., Toyama, K., Aul. C., Mufti, G. & Benne. J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89, 2079-2088.
12. Hansen, P.B., Johnsen. H.E., Hippe, E., Hellström-Lindberg, E. & Ralfkiaer, E. (1993) Recombinant human granulocytemacrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myclodysplastic syndromes. American Journal of Hematology. 44, 229-236. '
13. Hellström-Lindberg, E. (1995) Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. British Journal of Uaematology, 89, 67-71.
14. Hellström-Lindberg. E.. Ahlgrcn, T., Béguin, Y., Carlsson. M., Carneskog. J., Dabi, I.M., Dybedal, !.. Grimfors, G., KanterLewensohn, L., Linder, O., Luthman, M., Löfvenberg. E., NilssonEhle, H., Samuelsson. J., Tangen, J.M.. \Vinqvist, L, Öberg. G., Österborg, A. & Ost, A. (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 92, 68-75.
15. Kelley, L.L., Koury, M.J., Bondurant. M.C., Koury, S.T., Sawyer. S.T. & Wickrema, A. (1993) Survival or death of individual proerythroblasts results from differing erythropoietin sensitivities: a mechanism for controlled rates of erythrocyte production. Blood. 82, 2340-2352.
16. Kleinerman, E.S., Knowles. R.D., Lachman, L.B. & Gutterman, J.U. (1988) Effect of recombinant granulocyte/macrophage colonystimulating factor on human monocyte activity i;i vilro and following intravenous administration. Cancer Research, 48, 2604-2608.
17. Koury, M.J. & Bondurant, M.C. (1990) Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science. 248, 378-380.
18. Kurzrock, R., Talpaz, M., Estrov, Z., Rosenblum, M.G. & Gutterman, J.U. (1991) Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. Journal of Clinical Oncology, 9, 1241-1250.
19. Legare, R.D. & Gilliland. D.G. (1995) Myelodysplastic syndrome. Current Opinion in llematology, 2, 283-292.
20. Merchav. S., VVagemakér, G., Souza, L.M. & Tatarski, I. (1991) Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant hematopoietic growth factors. Leukemia, S, 340-346.
21. Miller, A.B., Hoogstraten, B., Staquet, M. & Winkler, A. (1981) Reporting results of cancer treatment. Cancer, 47, 207-214.
22. Negrin, R.S., Haeuber, D.H.. Nagler, A., Kobayashi. Y.. Sklar, J., Donlon, T., Vincent, M. & Greenberg. P. (1990) Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood. 76, 36-43.
23. Negrin, R.S., Stein, R., Doherty, K.. Cornwell, J., Vardiman, J., Krantz, S. & Greenberg. P. (1996) Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood, 87, 4076-4081.
24. Runde. V. Aul, C Ebert, A., Grabenhorst, U. & Schneider, W. (1995) Sequential administration of recombinant human granulocytemacrophage colony-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes. European Journal of Hnematology. 54, 39-45.
25. Schuster, M.W., Thompson, J.A., Larson, R., Coiffler, B.. Bennett, J.M. & Israel, R.J. (1990) A randomized trial of subcutaneous granulocyte-macrophage colony-stimulating factor versus observation in patients with myelodysplastic syndrome or aplastic anemia. (Abstract). Proceedings of the American Society of Clinical Oncology, 9, 205a.
26. Stasi, R.. Brunetti, M., Bussa, S., Conforti, M., Di Giulio, C., Crescenzi, A., Terzoli, E., Vecchione, A. & Pagano, A. (1997a) Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clinical Cancer Research, 3, 733-739.
27. Stasi. R., Brunetti, M., Bussa, S.. Conforti. M., Martin, L.S., La Presa, M., Blanchi. M.. Parma. A. & Pagano, A. (1997b) Serum levels of tumour necrosis factor- predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clinical and Laboratory Haemntology, 19, 197-201.
28. Stasi, R.. Del Poeta. G., Masi, M., Tribalto, M.. Vendittl, A., Papa. G.. Nicoletti, B., Vernole, P., Tedeschi, B., Delaroche, I.. Mingarelli, R. & Dallapiccola. B. (1993) Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genetics and Cytogenetics, 67, 28-34.
29. Thompson, J., Gilliland. G., Prchal, J., Bennett. J., Larholt, K., Nelson. R.. Rose. E. & Dugan, M. (1995) The use of GM-CSF ± r-HuEPO for the treatment of cytopenias associated with myelodysplastic syndromes. (Abstract). Blood, 86, (Suppl. 1), 337a.
30. Vadhan-Raj, S., Keating, M., LeMaistre, A.. Hittelman. W., McCredie, K.. Trujillo. J., Broxmeyer, H., Henney. C. & Gutterman, J. (1987) Effects of recombinant human granulocyte-macrophage colonystimulating factor in patients with myelodysplastic syndromes. New England Journal of Medicine. 317, 1545-1552.
31. Yoshida, Y.. Hirashima, K., Asano, S. & Takaku. E (1991) A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. British Journal of Haematokgy. 78, 378-384.